Joseph Munyi, a Kenyan citizen, has been living with HIV for 8 years and, much like other HIV patients, is unemployed. He has been receiving his medication free of charge on account of government programmes and outreach programmes of Medicine Sans Frontieres. His medication comes in the form of generic drugs. However, this situation may not last long as economic interests of few may end up impeding many a public spirited...
More »SEARCH RESULT
How PH Kurien took on global patents system to make very costly drug affordable for poor-Arvind Panagariya
It is said that only God and a few good men and women run India. One such man is P H Kurien. For readers unfamiliar with his name, Kurien was India's Controller General of Patents, Designs & Trade Marks until March 12, 2012. On March 9, 2012, just three days before he left office, he issued the first-ever compulsory licence in India for the manufacture of a drug still under patent....
More »Protests in US over high pricing of Novartis' anti-cancer drug Glivec-Divya Rajagopal
Health activists and cancer patients in the US have pounced on Swiss drug multinational Novartis for the high price of its famous, multi-billion dollar anti-cancer drug Glivec, a development which challenges pharma MNCs' claims of cheap access and affordability for patented drugs. Such protests, which began first in Europe, and have now spread to the US, could make it more difficult for pharma MNCs in developing countries to convince sceptical governments...
More »Bayer to challenge Cipla’s decision to cut price of cancer drug
-PTI German pharma major Bayer has charged that Indian generic drugmaker Cipla had breached its patent rights by slashing the price of a generic version of its patent-protected cancer drug Nexavar last week. Bayer Pharma has not given its consent to Cipla to launch its generic Sorafenib (sold under the brand name Nexavar) and the company’s decision to cut the price of the life-extending kidney and liver cancer drug “is a clear...
More »Malaria drug, made in India
-The Telegraph An Indian pharmaceutical company has tweaked and tested a synthetic molecule first created in an American university and developed the world's latest drug against malaria, an alternative to standard anti-malarial therapy. India’s Ranbaxy Laboratories today launched the new drug for the treatment of uncomplicated malaria caused by the Plasmodium falciparum parasite, after nine years of research which was partly supported by the Indian government. Clinical trials in India, Tanzania, and Thailand...
More »